Valsartan And Hydrochlorothiazide
Product Images NDC 50090-1422

9 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 50090-1422). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500901412)

Label Image (Lbl500901412)
Packaging label for Valsartan and Hydrochlorothiazide 160 mg/12.5 mg tablets by A-S Medication Solutions. The label states the product number 6480-0, quantity of 90 tablets, storage instructions to keep at 68 to 77 degrees Fahrenheit and protect from moisture, and includes a lot number and dosage instructions to see the package insert.*
FDA Label Image

Label Image (Lbl500901420)

Label Image (Lbl500901420)
Valsartan and Hydrochlorothiazide 80 mg/12.5 mg tablets packaging label from A-S Medication Solutions. The label lists product number 6485-0 and includes storage instructions to keep the tablets at 68 to 77 degrees Fahrenheit, protecting from moisture and heat. The package contains 90 tablets.*
FDA Label Image

Label Image (Lbl500901422)

Label Image (Lbl500901422)
Label for Valsartan and Hydrochlorothiazide 320 mg/12.5 mg tablets from A-S Medication Solutions. The label indicates the package contains 90 film-coated tablets with a lot number and storage instructions to protect the product from moisture and heat, storing at 68 to 77 degrees Fahrenheit.*
FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)
A line chart titled "Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8" showing the percentage of subjects with systolic blood pressure under 140 mmHg against baseline systolic blood pressure values ranging from 140 to 180 mmHg. Four lines represent different treatments: Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, with the combination treatment showing the highest probability across baselines.*
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure &lt;90 Mmhg At Week 8 (Valhyctz Fig2)

Figure 2: Probability Of Achieving Diastolic Blood Pressure &lt;90 Mmhg At Week 8 (Valhyctz Fig2)
A line graph showing the probability of achieving diastolic blood pressure (DBP) less than 90 mmHg across baseline DBP values from 90 to 110 mmHg. The graph includes four lines representing Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, with the combination therapy having the highest probability curve compared to others.*
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure &lt;130 Mmhg At Week 8 (Valhyctz Fig3)

Figure 3: Probability Of Achieving Systolic Blood Pressure &lt;130 Mmhg At Week 8 (Valhyctz Fig3)
A line graph depicting the probability of achieving systolic blood pressure (SBP) below 130 mmHg by week 8 for different treatments: Valsartan and Hydrochlorothiazide 320 mg/25 mg combination, Valsartan 320 mg alone, Hydrochlorothiazide 25 mg alone, and placebo. The x-axis shows baseline SBP in mmHg from 140 to 180, and the y-axis shows the percentage probability from 0 to 100.*
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure &lt;80 Mmhg At Week 8 (Valhyctz Fig4)

Figure 4: Probability Of Achieving Diastolic Blood Pressure &lt;80 Mmhg At Week 8 (Valhyctz Fig4)
A line graph showing the probability of achieving diastolic blood pressure (DBP) below 80 mmHg at week 8, plotted against baseline DBP in mmHg. It compares the effects of Valsartan and Hydrochlorothiazide 320 mg/25 mg combination, Valsartan 320 mg, Hydrochlorothiazide 25 mg alone, and placebo, with Valsartan and Hydrochlorothiazide combination showing the highest probability across baseline DBP values.*
FDA Label Image

Valsartan Chemical Structure (Valhyctz Str1)

Valsartan Chemical Structure (Valhyctz Str1)
Chemical structure of one active ingredient in Valsartan and Hydrochlorothiazide, depicting the molecular arrangement including rings, side chains, and functional groups of the compound.*
FDA Label Image

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)
Chemical structure of the active ingredient Valsartan and Hydrochlorothiazide, showing a complex molecular arrangement including sulfonamide and aromatic ring components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.